Author information:
(1)From Massachusetts General Hospital (L.J.W.) and Dana-Farber Cancer Institute 
(J. Lorch), Boston; Memorial Sloan Kettering Cancer Center, New York (E.S., 
A.D.); Royal North Shore Hospital, St. Leonards, NSW (B.R.), and Peter MacCallum 
Cancer Institute, Melbourne, VIC (B.S.) - both in Australia; University of 
California, San Francisco-Helen Diller Family Comprehensive Cancer Center, San 
Francisco (H.K.), David Geffen School of Medicine at UCLA, Los Angeles (J.W.G.), 
and Chao Family Comprehensive Cancer Center, University of California Irvine, 
Orange (V.W.Z.) - all in California; University of Michigan, Ann Arbor (F.W.), 
and START Midwest, Grand Rapids (N.L.) - both in Michigan; University of 
Pennsylvania, Philadelphia (M.B.); University of Chicago, Chicago (J.P.); 
Gustave Roussy, Villejuif (S.L.), Institut Bergonié, Bordeaux (Y.G.), Aix 
Marseille University, Centre National de la Recherche Scientifique, INSERM, 
Centre de Recherche en Cancérologie de Marseille, Assistance Publique-Hôpitaux 
de Marseille, Early Phase Cancer Trial Center CLIP2, Hospital La Timone, 
Marseille (F.B.), Centre Léon Bérard, Lyon (C.D.L.F.), and Hôpital Européen 
Georges-Pompidou, Faculté de Médecine Paris-Descartes, Paris (J.M.) - all in 
France; Mayo Clinic-Rochester, Rochester, MN (J.C.M.); Winship Cancer Institute 
of Emory University, Atlanta (T.K.O.); National Cancer Center Singapore, 
Singapore (D.S.W.T.); University of Bern, Bern, and Cantonal Hospital of 
Lucerne, Lucerne - both in Switzerland (O.G.); University of North 
Carolina-Chapel Hill, Chapel Hill (J.W.); University of Wisconsin-Carbone Cancer 
Center, Madison (M.E.B.); British Columbia Cancer Agency, Vancouver, Canada (J. 
Laskin); Oregon Health and Science University, Portland (M.H.T.); 
Universitätsklinikum Würzburg, Department of Internal Medicine I, Division of 
Endocrinology and Diabetology, Würzburg, Germany (M.K.); Sarah Cannon Research 
Institute-Tennessee Oncology, Nashville (T.M.B.); Johns Hopkins Kimmel Cancer 
Center, Washington, DC (B.L.); Fundación Jimenez Diaz, START-Madrid, Madrid 
(V.M.); Loxo Oncology, Stamford, CT (K.E., M.N., D.H., E.Y.Z., X.H., L.Y., J.K., 
S.M.R.); University of Texas M.D. Anderson Cancer Center, Houston (V.S., 
M.E.C.); and Ohio State University Comprehensive Cancer Center, Columbus 
(M.H.S.).